Low HDAC10 levels correlate with platinum sensitivity of tumors, and inhibition of HDAC10 enhances the efficacy of platinum chemotherapy in primary ovarian cancer cells (38). This evidence concerns the gene HDAC10 and ovarian carcinoma.